Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population

被引:19
作者
Ahmad, Firoz [1 ]
Mandava, Swarna [2 ]
Das, Bibhu Ranjan [1 ]
机构
[1] SRL Ranbaxy Ltd, Div Res & Dev, Bombay 400093, Maharashtra, India
[2] SRL Ranbaxy Ltd, Cytogenet Div, Bombay 400093, Maharashtra, India
关键词
NPM1; mutation; cytogenetic analysis; AML; India; ACUTE MYELOGENOUS LEUKEMIA; NUCLEOPHOSMIN MUTATIONS; TANDEM DUPLICATION; ADULT; AML; PREVALENCE; ASSOCIATION; EXPRESSION; STABILITY; PROGNOSIS;
D O I
10.1002/hon.883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the nucleophosmin (NPM1) gene have been recently described to occur in about one-third of acute myeloid leukaemias (AMLs) and represent the most frequent genetic alteration currently known in this subset, specially in those with normal karyotype. This study explored the prevalence and clinical profile of NPM1 mutations in a cohort of 200 Indian adult and children with AML. NPM1 mutations were observed in 19.5% of all population and 34.2% of those with normal karyotype. Adults had a significantly higher incidence of NPM1 mutations than children [38 of 161 (23.6%) vs. 1 of 39 (2.5%),p = 0.002]. NPM1 mutations were significantly associated with normal karyotype (p = 0.001), high WBC count (p = 0.034), AML-M4 subtype (p = 0.039) and a gradient increase of mutation rate with the increase in age groups. Sequence analysis of 39 mutated cases revealed typical mutations (types A, B, D, Nm and H*) as well as two novel variations (types F1 and F2). Majority of the patients had mutation type A (69.2%), followed by B (5.1%), D (15.3%), H* (2.5%) and Nm (2.5%) all involving COOH terminal of the NPM1 protein. In conclusion, this study represents the first report of NPM1 mutation from Indian population and confirms that the incidence of NPM1 mutations varies considerably globally, with slightly lower incidence in Indian population compared to western countries. The current study also served to identify two novel NPM1 mutants that add new insights into the heterogeneity of genomic insertions at exon 12. More ongoing larger studies are warranted to elucidate the molecular pathogenesis of AML that arises in this part of the world. Furthermore, we believe that in light of its high prevalence worldwide, inclusion of NPM1 mutation detection assay in diagnostic evaluations of AML may improve the efficacy of routine genetic characterization and allow assignment of patients to better-defined risk categories. Copyright (C) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:90 / 97
页数:8
相关论文
共 42 条
  • [1] Albiero E, 2006, HAEMATOLOGICA, V91, P237
  • [2] Beghini A, 2004, HAEMATOLOGICA, V89, P920
  • [3] Prevalence, clinical profile, and prognosis of NPM mutations in AML with normal karyotype
    Boissel, N
    Renneville, A
    Biggio, V
    Philippe, N
    Thomas, X
    Cayuela, JM
    Terre, C
    Tigaud, I
    Castaigne, S
    Raffoux, E
    De Botton, S
    Fenaux, P
    Dombret, H
    Preudhomme, C
    [J]. BLOOD, 2005, 106 (10) : 3618 - 3620
  • [4] Nucleophosmin mutation in Southeast Asian acute myeloid leukemia:: eight novel variants, FLT3 coexistence and prognostic impact of NPM1/FLT3 mutations
    Boonthimat, Chetsada
    Thongnoppakhun, Wanna
    Auewarakul, Chirayu U.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 (10): : 1565 - 1569
  • [5] ARF impedes NPM/B23 shuttling in an Mdm2-sensitive tumor suppressor pathway
    Brady, SN
    Yu, Y
    Maggi, LB
    Weber, JD
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (21) : 9327 - 9338
  • [6] The incidence and clinical significance of nucleophosmin mutations in childhood AML
    Brown, Patrick
    McIntyre, Emily
    Rau, Rachel
    Meshinchi, Soheil
    Lacayo, Norman
    Dahl, Gary
    Alonzo, Todd A.
    Chang, Myron
    Arceci, Robert J.
    Small, Donald
    [J]. BLOOD, 2007, 110 (03) : 979 - 985
  • [7] Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype
    Cazzaniga, G
    Dell'Oro, MG
    Mecucci, C
    Giarin, E
    Masetti, R
    Rossi, V
    Locatelli, F
    Martelli, MF
    Basso, G
    Pession, A
    Biondi, A
    Falini, B
    [J]. BLOOD, 2005, 106 (04) : 1419 - 1422
  • [8] Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
    Cheson, BD
    Bennett, JM
    Kopecky, KJ
    Büchner, T
    Willman, CL
    Estey, EH
    Schiffer, CA
    Döhner, H
    Tallman, MS
    Lister, TA
    LoCocco, F
    Willemze, R
    Biondi, A
    Hiddemann, W
    Larson, RA
    Löwenberg, B
    Sanz, MA
    Head, DR
    Ohno, R
    Bloomfield, CD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4642 - 4649
  • [9] Nucleophosmin mutations in De novo acute myeloid leukemia:: The age-dependent incidences and the stability during disease
    Chou, WC
    Tang, JL
    Lin, LI
    Yao, M
    Tsay, W
    Chen, CY
    Wu, SJ
    Huang, CF
    Chiou, RJ
    Tseng, MH
    Lin, DT
    Lin, KH
    Chen, YC
    Tien, HF
    [J]. CANCER RESEARCH, 2006, 66 (06) : 3310 - 3316
  • [10] Nucleophosmin regulates the stability and transcriptional activity of p53
    Colombo, E
    Marine, JC
    Danovi, D
    Falini, B
    Pelicci, PG
    [J]. NATURE CELL BIOLOGY, 2002, 4 (07) : 529 - 533